DNA minigene vaccination for adjuvant neuroblastoma therapy

Annals of the New York Academy of Sciences

Volumn 1028, Issue , 2004, Pages 113-121

  Lode, Holger N ^a   Huebener, Nicole ^a   Zeng, Yan ^a   Fest, Stefan ^a   Weixler, S ^a   Gaedicke, Gerhard ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

DNA vaccination; Neuroblastoma; Tyrosine hydroxylase

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CATECHOLAMINE; CD40 ANTIGEN; CD40 LIGAND; CD8 ANTIGEN; CYTOKINE; DNA VACCINE; DOPA; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PLASMID DNA; RIBONUCLEOTIDE REDUCTASE; TUMOR NECROSIS FACTOR ALPHA; TYROSINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL MODEL; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CATALYSIS; CATECHOLAMINE SYNTHESIS; CONFERENCE PAPER; ENZYME ACTIVITY; GROWTH INHIBITION; IMMUNE SYSTEM; LIVER METASTASIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; SALMONELLA TYPHIMURIUM; TANDEM MASS SPECTROMETRY; TUMOR GROWTH; VACCINATION;

ANIMALIA; MAMMALIA; MURINAE; SALMONELLA TYPHIMURIUM; TYPHIMURIUM;

EID: 14944354859     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1322.012     Document Type: Conference Paper

References (38)

1. YU, A.L., M.M. UTTENREUTHER-FISCHER, C.S. HUANG, et al. 1998. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J. Clin. Oncol. 16: 2169-2180.
2. HANDGRETINGER, R., K. ANDERSON, P. LANG, et al. 1995. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur. J. Cancer 31A: 261-267.
3. CHEUNG, N.K., H.F. GUO, G. HELLER & I.Y. CHEUNG. 2000. Induction of Ab3 and Ab3′ antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma Clin. Cancer Res. 6: 2653-2660.
4. TIGHE, H., M. CORR, M. ROMAN & E. RAZ. 1998. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol. Today 19: 89-97.
5. ROBINSON, H.L. & C.A. TORRES. 1997. DNA vaccines. Semin. Immunol. 9: 271-283.
6. LODE, H.N., U. PERTL, R. XIANG, et al. 2000. Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma. Med. Pediatr. Oncol. 35: 641-646.
7. BLANKENSTEIN, T., S. CAYEUX & Z. QIN. 1996. Genetic approaches to cancer immunotherapy. Rev. Physiol. Biochem. Pharmacol. 129: 1-49.
8. ROBINSON, H.L. & C.A. TORRES. 1997. DNA vaccines. Semin. Immunol. 9: 271-283.
9. KRIEG, A.M., A.K. YI, J. SCHORR & H.L. DAVIS. 1998. The role of CpG dinucleotides in DNA vaccines. Trends Microbiol. 6: 23-27.
10. LOWRIE, D.B. 1998. DNA vaccination exploits normal biology. Nat. Med. 4: 147-148.
11. RAZ, E. 1997. Introduction: gene vaccination, current concepts and future directions. Springer Semin. Immunopathol. 19: 131-137.
12. TIOHE, H., M. CORR, M. ROMAN & E. RAZ. 1998. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol. Today 19: 89-97.
13. SIZEMORE, D.R., A.A. BRANSTROM & J.C. SADOFF. 1997. Attenuated bacteria as a DNA delivery vehicle for DNA-mediated immunization Vaccine 15: 804-807.
14. DARJI, A., C.A. GUZMAN, B. GERSTEL, et al. 1997. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 91: 765-775.
15. DIETRICH, G., A. BUBERT, I. GENTSCHEV, et al. 1998. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogencs. Nat. Biotechnol 16: 181-185.
16. KAUFMANN, S.H. 1993. Immunity to intracellular bacteria. Annu. Rev. Immunol. 11: 129-163.
17. MATZINGER, P. 1994. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12: 991-1045.
18. RODRIOUEZ, F., J. ZHANG & J.L. WHITTON. 1997. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J. Virol. 71: 8497-8503.
19. LODE, H.N., U. PERTL, R. XIANG, et al. 2000. Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma. Med. Pediatr. Oncol. 35: 641-646.
20. VARSHAVSKY, A. 1992. The N-end rule. Cell 69: 725-735.
21. VARSHAVSKY, A. 1991. Naming a targeting signal. Cell 64: 13-15.
22. GONDA, D.K., A. BACHMAIR, I. WUNNING, et al. 1989. Universality and structure of the N-end rule. J Biol. Chem. 264: 16700-16712.
23. JOHNSON, E.S., P.C. MA, I.M. OTA & A. VARSHAVSKY. 1995. A proteolytic pathway that recognizes ubiquitin as a degradation signal. J. Biol. Chem. 270: 17442-17456.
24. COX, J.H., P. GALARDY, J.R. BENNINK & J.W. YEWDELL. 1995. Presentation of endogenous and exogenous antigens is not affected by inactivation of E1 ubiquitin-activating enzyme in temperature-sensitive cell lines. J. Immunol. 154: 511-519.
25. GOODING, L.R. & C.B. EDWARDS. 1980. H-2 antigen requirements in the in vitro induction of SV40-specific cytotoxic T lymphocytes. J. Immunol. 124: 1258-1262.
26. HUANG, A.Y., P. GOLUMBEK, M. AHMADZADEH, et al. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264: 961-965.
27. HUANG, A.Y., P. GOLUMBEK, M. AHMADZADEH, et al. 1994. Bone marrow-derived cells present MHC class I-restricted tumour antigens in priming of antitumour immune responses. Ciba Found. Symp. 187: 229-240.
28. BECKER, J.C., J.D. PANCOOK, S.D. GILLIES, et al. 1996. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J. Exp. Med. 183: 2361-2366.
29. XIANG, R., H.N. LODE, C.S. DOLMAN, et al. 1997. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res 57: 4948-4955.
30. BECKER, J.C., N.M. VARKI, S.D. GILLIES, et al. 1997. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J. Clin. Invest. 98: 2801-2804.
31. XIANG, R., H.N. LODE, S.D. GILLIES & R.A. REISFELD. 1999. T cell memory against colon carcinoma is long-lived in the absence of antigen. J. Immunol. 163: 3676-3683.
32. LODE, H.N., R. XIANG, N.M. VARKI, et al. 1997. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J. Natl. Cancer Inst. 89: 1586-1594.
33. LODE, H.N., R. XIANG, T. DREIER, et al. 1998. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 91: 1706-1715.
34. LODE, H.N., T. DREIER, R. XIANG, et al. 1998. Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Proc. Natl. Acad. Sci. USA. 95: 2475-2480.
35. LODE, H.N., R. XIANG, S.R. DUNCAN, et al. 1999. Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. Proc. Natl. Acad. Sci. USA 96: 8591-8596.
36. BALICKI, D., R.A. REISFELD, U. PERTL, et al. 2000. Histone H2A-mediated transient cytokine gene delivery induces efficient antitumor responses in murine neuroblastoma. Proc. Natl. Acad. Sci. USA 97: 11500-11504.
37. PERTL, U., H. WODRICH, J.M. RUEHLMANN, et al. 2003. Immunotherapy with a post-transcriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma. Blood 101: 649-654.
38. HOLZHUTTER, H.G., C. FROMMEL & P.M. KLOETZEL. 1999. A theoretical approach towards the identification of cleavage-determining amino acid motifs of the 20 S proteasome. J. Mol. Biol. 286: 1251-1265.